BioNTech Net Income Applicable To Common Shares from 2010 to 2026
| 22UA Stock | EUR 93.05 2.20 2.31% |
Net Income Applicable To Common Shares | First Reported 2010-12-31 | Previous Quarter 11.8 B | Current Value 12.4 B | Quarterly Volatility 5.4 B |
Check BioNTech financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among BioNTech's main balance sheet or income statement drivers, such as Interest Income of 528.4 M, Interest Expense of 15.2 M or Selling General Administrative of 723.3 M, as well as many indicators such as Price To Sales Ratio of 10.38, Dividend Yield of 0.011 or PTB Ratio of 1.27. BioNTech financial statements analysis is a perfect complement when working with BioNTech Valuation or Volatility modules.
BioNTech | Net Income Applicable To Common Shares |
The Net Income Applicable To Common Shares trend for BioNTech SE offers valuable insights into the company's financial trajectory and strategic direction. By examining multi-year patterns, investors can identify whether BioNTech is strengthening or weakening its position, and how this metric correlates with broader market conditions and industry benchmarks.
Latest BioNTech's Net Income Applicable To Common Shares Growth Pattern
Below is the plot of the Net Income Applicable To Common Shares of BioNTech SE over the last few years. It is the net income that remains after preferred dividends have been deducted, available to common shareholders. BioNTech's Net Income Applicable To Common Shares historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in BioNTech's overall financial position and show how it may be relating to other accounts over time.
| Net Income Applicable To Common Shares | 10 Years Trend |
|
Net Income Applicable To Common Shares |
| Timeline |
BioNTech Net Income Applicable To Common Shares Regression Statistics
| Arithmetic Mean | 3,796,319,162 | |
| Geometric Mean | 431,577,712 | |
| Coefficient Of Variation | 143.28 | |
| Mean Deviation | 5,018,429,856 | |
| Median | (85,653,000) | |
| Standard Deviation | 5,439,385,519 | |
| Sample Variance | 29586914.8T | |
| Range | 12.6B | |
| R-Value | 0.84 | |
| Mean Square Error | 9132020T | |
| R-Squared | 0.71 | |
| Significance | 0.000021 | |
| Slope | 908,039,174 | |
| Total Sum of Squares | 473390637.2T |
BioNTech Net Income Applicable To Common Shares History
About BioNTech Financial Statements
BioNTech stakeholders use historical fundamental indicators, such as BioNTech's Net Income Applicable To Common Shares, to determine how well the company is positioned to perform in the future. Although BioNTech investors may analyze each financial statement separately, they are all interrelated. For example, changes in BioNTech's assets and liabilities are reflected in the revenues and expenses on BioNTech's income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in BioNTech SE. Please read more on our technical analysis and fundamental analysis pages.
| Last Reported | Projected for Next Year | ||
| Net Income Applicable To Common Shares | 11.8 B | 12.4 B |
Currently Active Assets on Macroaxis
When determining whether BioNTech SE offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of BioNTech's financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Biontech Se Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Biontech Se Stock:Check out the analysis of BioNTech Correlation against competitors. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.